Company Number: 13131664

Analysis Date: 2025-07-19 13:04 UTC

1. Credit Opinion: APPROVE with conditions
   Biolab London Ltd shows a positive financial trajectory with improving net assets and working capital over the last three years. The company is micro-sized, recently established (2021), and operates in the professional testing and beauty treatment sector. It has no history of overdue filings and demonstrates adequate management continuity with no adverse director records. However, given its small scale, limited fixed assets, and modest net assets (£12,175 at 2024 year-end), credit approval should be conditional on ongoing monitoring of cash flow and receivables to ensure continued liquidity, especially considering sector risks linked to Covid-19 testing demand variability.

2. Financial Strength:
   The company’s balance sheet is modest but improving. Net assets increased significantly from £1,186 in 2023 to £12,175 in 2024, driven by improved net current assets (£12,772 in 2024 vs £7,666 in 2023). Fixed assets are negligible, indicating limited capital investment, which is common for micro entities in this service sector. There is a small long-term creditor balance (£597 in 2024 down from £6,805 in 2023), reducing leverage risk. Shareholders’ funds have grown, reflecting retained profits and strengthening equity. Overall, the financial position is sound for its size but lacks depth for extended credit risk exposure.

3. Cash Flow Assessment:
   Current assets of £35,524 against current liabilities of £22,752 yield positive net current assets (£12,772), indicating adequate short-term liquidity. The increase in current assets suggests improved cash or receivables management. The company has a small workforce (average 3 employees) and presumably limited fixed overheads, which supports manageable operating cash requirements. However, absence of detailed cash flow statements restricts full assessment. The company's ability to meet short-term obligations appears sufficient, but cash flow should be closely reviewed especially if business volumes fluctuate.

4. Monitoring Points:

• Follow up on accounts filing and confirmation statements to ensure continued compliance.
• Monitor net current assets and liquidity ratios quarterly to detect any deterioration.
• Watch for changes in trade creditors and debtor aging to assess cash cycle risk.
• Track sector demand shifts, particularly Covid-19 testing volumes, as this impacts revenue stability.
• Review management actions on cost control and revenue diversification to mitigate market risk.